Antipaletet drug
PreclinicalSmall molecule
Antipaletet drug is one of 11 small molecule programs targeting Patent foramen ovale. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Patent Foramen Ovale
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Xarelto
WWim Janssens
Approved
Coumadin
AAbbott
Approved
Viagra
VViatris Specialty LLC
Approved
Tambocor
AAlvogen Korea
Phase 3
Eliquis
Bristol-Myers SquibbPhase 2
Best Medical Therapy
UUniversity of North Carolina, Chapel Hill
Phase 3
Bayer Aspirin
BayerPreclinical
Conservative Treatment
PPeking University Third Hospital
Preclinical
Medication
NNYU Langone Health
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antipaletet drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University Third Hospital